

AUG 2 8 2001

510k Submission  
WH ACCU TEST  
W.H.P.M. Inc.

Page 18 of 31

K012284

## 510 (K) SUMMARY

**Date of Summary:** July 18, 2001

**Product Name:**

WH Accu Test™ Pregnancy Test

**Sponsor:**

W.H.P.M. Inc  
2540 Corporate Place  
Suite B107  
Monterey Park, CA 91754

**Correspondent:**

MDC Associates  
Fran White  
Regulatory Consultant  
163 Cabot Street  
Beverly, MA 01915

**Substantially Equivalent Devices:**

**Product:** SURE VUE  
**Manufactured by:** Fisher Diagnostics

### PRODUCT DESCRIPTION:

The WH Accu Test™ Pregnancy Test is to be used for detecting human Chorionic Gonadotropin (hCG) in urine. The presence of hCG usually appears about the seventh day after fertilization. The WH Accu Test™ Pregnancy Test will detect hCG in urine at a concentration level of 25 mIU/ml. The WH Accu Test™ Pregnancy Test will be sold for professional use only.

**INTENDED USE:**

The WH Accu Test™ Pregnancy Test is a test for the qualitative determination of human chorionic gonadotropin (hCG) in urine for the early detection of pregnancy. **For Laboratory Professional Use Only.**

**SUMMARY OF TECHNOLOGY:**

The WH Accu Test™ Pregnancy Test employs a unique combination of monoclonal-dye conjugate and polyclonal-solid phase antibodies to selectively identify human Chorionic Gonadotropin (hCG) in urine. As the urine sample flows through the absorbent portion of the device, the antibody-dye conjugate binds to the hCG forming an antibody-antigen complex. This complex binds to the anti-hCG antibody in the positive reaction zone and produces a pink-rose color band if hCG concentration is equal to or greater than 25 mIU/ml. In the absence of hCG, there is no line in the reaction zone. Unbound conjugate binds to the reagents in the control zone, producing a pink-rose color band, demonstrating that the reagents are functioning correctly.

**PERFORMANCE DATA:**

A clinical trial was done to compare the performance of The WH Accu Test™ Pregnancy Test. These data clearly demonstrate that the performance of the WH Accu Test™ Pregnancy Test by W.H.P.M. Inc. is substantially equivalent to the Fisher SURE VUE.

|               |      |
|---------------|------|
| Sensitivity = | 100% |
| Specificity = | 100% |
| Agreement =   | 100% |

**STATEMENT OF SAFETY AND EFFICACY:**

The WH Accu Test™ Pregnancy Test when compared with another commonly used pregnancy test (Fisher SURE VUE) demonstrated 100% performance.

These data clearly demonstrate the safety and efficacy of the WH Accu Test™ Pregnancy Test and further confirm the accuracy, sensitivity and specificity of this product, when compared to a substantially equivalent device currently being sold for professional use. A trained Laboratory Technician performed testing in a CLIA registered laboratory.

**W.H.P.M. Inc confirms that any/all data provided in this submission may be released upon request.**



DEPARTMENT OF HEALTH & HUMAN SERVICES

AUG 2 8 2001

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

W.H.P.M., Inc.  
c/o Ms. Fran White  
Regulatory Consultant  
MDC Associates  
163 Cabot Street  
Beverly, MA 01915

Re: K012284  
Trade/Device Name: WH Accu Test <sup>TM</sup> Pregnancy Test  
Regulation Number: 21 CFR 862.1155  
Regulatory Class: II  
Product Code: JHI  
Dated: July 18, 2001  
Received: July 20, 2001

Dear Ms. White:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895.


A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 -

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in dark ink, reading "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.  
Director  
Division of Clinical Laboratory Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

510k Submission - Request for Additional Information

K012284

WH Accu Test Pregnancy Test  
W.H.P.M. Inc.

Page 6 of 11

**Device Name:** The WH Accu Test™ Pregnancy Test

**Indication for Use:**

The WH Accu Test™ Pregnancy Test is a test for the qualitative determination of human chorionic gonadotropin (hCG) in urine for the early detection of pregnancy. **For Laboratory Professional Use Only. This device is not for use in the Over the Counter market.**

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

**Concurrence of CDRH, Office of Device Evaluation (ODE)**

Prescription Use ✓  
(Per 21 CFR 801.109)

OR

Over The Counter Use \_\_\_\_\_  
(Optional Format 1-2-96)

Kesia Alexander for Jean Cayer  
(Division Sign-Off)  
Division of Clinical Laboratory Devices  
510(k) Number K012284